SAS Drug Development Adds Genomic-Analysis Capabilities
Solution addresses biomarkers, incorporates molecular information
PHILADELPHIA, June 19, 2006-SAS, the leader in business intelligence, today announced new genomic-analysis capabilities for its flagship life sciences offering, SAS® Drug Development. These new capabilities will make it easier for pharmaceutical companies to analyze genetic data and incorporate this analysis into new drug applications.
SAS Drug Development is a powerful data management and analysis solution for pharmaceutical, medical device and biotechnology firms. More than 90 processes for genomic and proteomic-specific molecular analyses-powered by JMP® software-are now incorporated into SAS Drug Development, addressing the areas of:
- Genetics. For genetic marker data, case-control or pedigree experiments. Useful for characterizing genetic variability and evaluating its association with biological effects, such as disease or adverse events.
- Microarrays. For gene expression or RNA transcript abundance data. Useful for investigating gene utilization to understand disease or biological processes.
- Proteomics. For spectral data on peptides or metabolites. Useful for identifying protein biomarkers and their association with disease or traits.
Articles in this issue
about 19 years ago
Article
INC Research Latest Organization to Partner with SAS in Life Science IndustryNewsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025